Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Takashi Mizuoka, Hiroyuki Sakamaki, Shigeo Fuji, Shota Saito, Tatsunori Murata, Shinya Ohno, Naoki Inubashiri, Tomoha Oshima & Kazuhito Yamamoto. (2023) Cost-effectiveness of combination therapy of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisolone for previously untreated diffuse large B-cell lymphoma in Japan. Journal of Medical Economics 26:1, pages 1122-1133.
Read now
Read now
Luxitaa Goenka, S. Mathan Kumar, Saravanan Essakky, Subramania Raju Rajasulochana, Parthibane Sivanantham, Reshma Ayiraveetil, Sitanshu Sekhar Kar & Prasanth Ganesan. (2023) Cost-effectiveness of response-adapted therapy (RAT) for advanced Hodgkin’s Lymphoma compared with conventional treatment in India: a Markov-model based analysis. Leukemia & Lymphoma 0:0, pages 1-7.
Read now
Read now
Jia Liu, Lei Zheng & Ling-Hsiang Chuang. (2022) Cost-effectiveness of brentuximab vedotin for relapsed or refractory systemic anaplastic large-cell lymphoma in China. Journal of Medical Economics 25:1, pages 99-107.
Read now
Read now
Thomas E. Delea, Arati Sharma, Aaron Grossman, Caitlin Eichten, Keenan Fenton, Neil Josephson, Akshara Richhariya & Alison J. Moskowitz. (2019) Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage III or IV classical Hodgkin lymphoma. Journal of Medical Economics 22:2, pages 117-130.
Read now
Read now
Samuel Large, Robert Hettle, Arun Balakumaran, Elise Wu & Rebekah H. Borse. (2019) Cost-effectiveness of pembrolizumab versus brentuximab vedotin for patients with relapsed or refractory classical Hodgkin’s lymphoma: a United States payer perspective. Journal of Medical Economics 22:1, pages 16-25.
Read now
Read now
Andrei Krassioukov, Yasuhiko Igawa, Márcio Augusto Averbeck, Helmut Madersbacher, Andrew J Lloyd, Mette Bøgelund & Nikesh Thiruchelvam. (2018) Gains in health utility associated with urinary catheter innovations. Medical Devices: Evidence and Research 11, pages 345-351.
Read now
Read now
Christopher Parker, Beth Woods, James Eaton, Esprit Ma, Ross Selby, Eugene Benson, Andreas Engstrom, Peter Sajosi, Andrew Briggs & Vijayveer Bonthapally. (2017) Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant: a cost-effectiveness analysis in Scotland. Journal of Medical Economics 20:1, pages 8-18.
Read now
Read now
Articles from other publishers (13)
David Elsea, Kerry J. Savage, Cameron Lilley, Julie Lisano, Jingmin Liu & Kristina S. Yu. (2023) Cost-Effectiveness of Brentuximab Vedotin Versus Physician’s Choice of Methotrexate or Bexarotene for the Treatment of Cutaneous T-cell Lymphoma in Canada. Advances in Therapy 40:5, pages 2326-2338.
Crossref
Crossref
Clayton P. Smith, Bethel Adefres, Eric M. Chang, Tina Q. Huang, Neil Parikh & Ann Raldow. (2022) Cost-Effectiveness of PET Directed Versus Combined Modality Therapy for Early-Stage Favorable Hodgkin's Lymphoma. Clinical Lymphoma Myeloma and Leukemia 22:11, pages e992-e999.
Crossref
Crossref
Holly Cranmer, David Trueman, Elise Evers, Fionn Woodcock & Tanja Podkonjak. (2022) Brentuximab Vedotin Plus CHP in Frontline sALCL: Adjusted Estimates of Efficacy and Cost-Effectiveness Removing the Effects of Re-Treatment with Brentuximab Vedotin. PharmacoEconomics - Open 6:6, pages 881-892.
Crossref
Crossref
Adrian Peacock, Francis Dehle, Oscar Alejandro Mesa Zapata, H. Miles Prince, Francesca Gennari & Colman Taylor. (2022) Cost-Effectiveness of Extracorporeal Photopheresis for the Treatment of Patients With Erythrodermic (Stage T4, M0) Cutaneous T-Cell Lymphoma in the Australian Setting. Value in Health 25:6, pages 965-974.
Crossref
Crossref
Tanja Podkonjak, Holly Cranmer, Julia Scarisbrick, Grant McCarthy, Cameron Lilley & Lung-I Cheng. (2022) Cost–effectiveness of brentuximab vedotin for the treatment of cutaneous T-cell lymphoma. Journal of Comparative Effectiveness Research 11:3, pages 193-202.
Crossref
Crossref
Raymond B. Mailhot Vega, Homan Mohammadi, Samir I. Patel, Adam L. Holtzman, Natalie A. Lockney, James W. Lynch, Manisha M. Bansal, Xiaoying Liang, William B. Slayton, Susan K. Parsons, Bradford S. Hoppe & Nancy P. Mendenhall. (2022) Establishing Cost-Effective Allocation of Proton Therapy for Patients With Mediastinal Hodgkin Lymphoma. International Journal of Radiation Oncology*Biology*Physics 112:1, pages 158-166.
Crossref
Crossref
Seonyoung Park, Ah-Young Kim, Hyeonseok Cho, Deborah Baik, Hankil Lee, Sunghwa Cho & Hye-Young Kang. (2020) Cost-utility analysis of pralatrexate for relapsed or refractory peripheral T-cell lymphoma based on a case-matched historical control study along with single arm clinical trial. BMC Cancer 20:1.
Crossref
Crossref
A. J. N. Raymakers, S. Costa, D. Cameron & D. A. Regier. (2020) Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin’s lymphoma: a probabilistic analysis. BMC Cancer 20:1.
Crossref
Crossref
Angela Stainthorpe, Nigel Fleeman, Rachel Houten, Marty Chaplin, Angela Boland, Sophie Beale, Yenal Dundar, Joanne McEntee & Isabel Syndikus. (2020) Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics - Open 4:4, pages 563-574.
Crossref
Crossref
Sabine E. Grimm, Debra Fayter, Bram L. T. Ramaekers, Svenja Petersohn, Rob Riemsma, Nigel Armstrong, Xavier Pouwels, Willem Witlox, Caro Noake, Gillian Worthy, Jos Kleijnen & Manuela A. Joore. (2019) Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics 37:10, pages 1195-1207.
Crossref
Crossref
Scott F. HuntingtonGottfried von KeudellAmy J. DavidoffCary P. GrossSapna A. Prasad. (2018) Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma. Journal of Clinical Oncology 36:33, pages 3307-3314.
Crossref
Crossref
Lucy Hui, Gottfried von Keudell, Rong Wang, Amer M. Zeidan, Steven D. Gore, Xiaomei Ma, Amy J. Davidoff & Scott F. Huntington. (2017) Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation. Cancer 123:19, pages 3763-3771.
Crossref
Crossref
Margaret Hux, Denise Zou, Esprit Ma, Peter Sajosi, Andreas Engstrom, Selby Ross, Eugene Benson, Andrew Briggs & Vijayveer Bonthapally. (2016) A Cost-effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. Journal of Health Economics and Outcomes Research 4:2, pages 188-203.
Crossref
Crossref